Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Human B Cells Engage the NCK/PI3K/RAC1 Axis to Internalize Large Particles via the IgM-BCR.

Verstegen NJM, Unger PA, Walker JZ, Nicolet BP, Jorritsma T, van Rijssel J, Spaapen RM, de Wit J, van Buul JD, Ten Brinke A, van Ham SM.

Front Immunol. 2019 Mar 13;10:415. doi: 10.3389/fimmu.2019.00415. eCollection 2019.

2.

T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells.

Pont MJ, Oostvogels R, van Bergen CAM, van der Meijden ED, Honders MW, Bliss S, Jongsma MLM, Lokhorst HM, Falkenburg JHF, Mutis T, Griffioen M, Spaapen RM.

Cancer Immunol Res. 2019 May;7(5):797-804. doi: 10.1158/2326-6066.CIR-18-0137. Epub 2019 Mar 19.

PMID:
30890530
3.

The Role of Glycosphingolipids in Immune Cell Functions.

Zhang T, de Waard AA, Wuhrer M, Spaapen RM.

Front Immunol. 2019 Jan 29;10:90. doi: 10.3389/fimmu.2019.00090. eCollection 2019. Review.

4.

Secretome Screening Reveals Fibroblast Growth Factors as Novel Inhibitors of Viral Replication.

van Asten SD, Raaben M, Nota B, Spaapen RM.

J Virol. 2018 Jul 31;92(16). pii: e00260-18. doi: 10.1128/JVI.00260-18. Print 2018 Aug 15.

5.

CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.

Thielen AJF, van Baarsen IM, Jongsma ML, Zeerleder S, Spaapen RM, Wouters D.

J Immunol Methods. 2018 May;456:15-22. doi: 10.1016/j.jim.2018.02.004. Epub 2018 Feb 12.

PMID:
29447841
6.

The regulatory network behind MHC class I expression.

Jongsma MLM, Guarda G, Spaapen RM.

Mol Immunol. 2019 Sep;113:16-21. doi: 10.1016/j.molimm.2017.12.005. Epub 2017 Dec 8.

7.

An ER-Associated Pathway Defines Endosomal Architecture for Controlled Cargo Transport.

Jongsma ML, Berlin I, Wijdeven RH, Janssen L, Janssen GM, Garstka MA, Janssen H, Mensink M, van Veelen PA, Spaapen RM, Neefjes J.

Cell. 2016 Jun 30;166(1):152-66. doi: 10.1016/j.cell.2016.05.078.

8.

Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma.

Scanu T, Spaapen RM, Bakker JM, Pratap CB, Wu LE, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, Song JY, Neefjes-Borst EA, te Riele H, Holden DW, Nath G, Neefjes J.

Cell Host Microbe. 2015 Jun 10;17(6):763-74. doi: 10.1016/j.chom.2015.05.002. Epub 2015 May 28.

9.

Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.

Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, Ekkebus R, Rijal P, Celie PH, Huang JH, Emmelot ME, Spaapen RM, Lokhorst H, Schumacher TN, Mutis T, Rodenko B, Ovaa H.

J Immunol. 2014 Nov 15;193(10):4803-13. doi: 10.4049/jimmunol.1400800. Epub 2014 Oct 13.

10.

Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature.

Spaapen RM, Leung MY, Fuertes MB, Kline JP, Zhang L, Zheng Y, Fu YX, Luo X, Cohen KS, Gajewski TF.

J Immunol. 2014 Oct 15;193(8):4254-60. doi: 10.4049/jimmunol.1401109. Epub 2014 Sep 12.

11.

Identification of minor histocompatibility antigens based on the 1000 Genomes Project.

Oostvogels R, Lokhorst HM, Minnema MC, van Elk M, van den Oudenalder K, Spierings E, Mutis T, Spaapen RM.

Haematologica. 2014 Dec;99(12):1854-9. doi: 10.3324/haematol.2014.109801. Epub 2014 Aug 22.

12.

Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes.

Hassan C, Kester MG, Oudgenoeg G, de Ru AH, Janssen GM, Drijfhout JW, Spaapen RM, Jiménez CR, Heemskerk MH, Falkenburg JH, van Veelen PA.

J Proteomics. 2014 Sep 23;109:240-4. doi: 10.1016/j.jprot.2014.07.009. Epub 2014 Jul 19.

PMID:
25050860
13.

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF.

Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504.

14.

Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.

Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF.

Mol Immunol. 2013 Oct;55(3-4):283-91. doi: 10.1016/j.molimm.2013.03.006. Epub 2013 Mar 30. Erratum in: Mol Immunol. 2013 Dec;56(4):530.

15.

Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T.

Leukemia. 2013 Mar;27(3):642-9. doi: 10.1038/leu.2012.277. Epub 2012 Oct 1.

16.

Immuno-waste exposure and further management.

Spaapen RM, Neefjes J.

Nat Immunol. 2012 Jan 19;13(2):109-11. doi: 10.1038/ni.2204. No abstract available.

PMID:
22261957
17.

Functional characteristics of the high affinity IgG receptor, FcγRI.

van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH.

J Immunol. 2011 Mar 1;186(5):2699-704. doi: 10.4049/jimmunol.1003526. Review.

18.

Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen.

Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T, Bloem AC, Storm G, Martens AC, Lokhorst HM, Mutis T.

Clin Cancer Res. 2010 Nov 15;16(22):5481-8. doi: 10.1158/1078-0432.CCR-10-1340. Epub 2010 Nov 9.

19.

Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis.

Spaapen RM, de Kort RA, van den Oudenalder K, van Elk M, Bloem AC, Lokhorst HM, Mutis T.

Clin Cancer Res. 2009 Dec 1;15(23):7137-43. doi: 10.1158/1078-0432.CCR-09-1914. Epub 2009 Nov 24.

20.

Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.

Spaapen RM, Lokhorst HM, van den Oudenalder K, Otterud BE, Dolstra H, Leppert MF, Minnema MC, Bloem AC, Mutis T.

J Exp Med. 2008 Nov 24;205(12):2863-72. doi: 10.1084/jem.20080713. Epub 2008 Nov 10.

Supplemental Content

Loading ...
Support Center